Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors.
about
Who is fit for allogeneic transplantation?Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblingsTransplantation for myelodysplastic syndrome in the era of hypomethylating agents.Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematolPhase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting.Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how?Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: the past decade.Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromesTreatment strategies in myelodysplastic syndromes.Long term follow-up of allogeneic stem cell transplantation in patients with myelodysplastic syndromes using busulfan, cytosine arabinoside, and cyclophosphamide.Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysisMyeloablative hematopoietic stem cell transplantation improves survival but is not curative in a pre-clinical model of myelodysplastic syndrome.Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.188Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia.Lack of cytoprotective effect of amifostine following HLA-identical sibling transplantation for advanced myelodysplastic syndrome (MDS): a pilot study.Thiotepa/cyclophosphamide/TBI as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome.Effects of prednisolone on the dystrophin-associated proteins in the blood-brain barrier and skeletal muscle of dystrophic mdx mice.Feasibility study on dosimetry verification of volumetric-modulated arc therapy-based total marrow irradiation.Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia.Long-term outcomes of allogeneic hematopoietic cell transplantation with intensified myeloablative conditioning for refractory myeloid malignancy.Peripheral blood is safer than bone marrow as a source of hematopoietic progenitors in patients with myelodysplastic syndromes who receive an allogeneic transplantation. Results from the Spanish registry
P2860
Q35660739-5DB637A7-CD4B-486D-B2E7-904F31C187B6Q35838113-A3FF6B44-D634-40C8-A3E8-DCACA8125DF6Q35854094-B28D3C4C-7217-49C7-BE40-C763D3EFD2DFQ35925067-44411ED6-EDE1-4622-B049-D77DEF6415CAQ36341861-B90909D1-E711-4995-A7FF-E74815C3F260Q36431041-C4A71AC4-67E8-4A71-8889-F59F99FB24BCQ36811828-F21DEC92-63C0-42FE-9B70-D6276A3E8800Q36984304-E859BDF2-62A2-4773-9A42-30CD12D1C03CQ37079916-DF34C4F8-6C00-47C1-B5A7-77958392209FQ37238484-DCA97BEA-8783-4DF7-B7BF-04A13A76758FQ37301516-04D97E0F-9057-4835-8DBD-5C01A1CDDADEQ42025658-9F680651-CCD2-4B1D-8404-D070535D16B7Q43666936-1109BB8A-F6A2-4287-8357-1BB88AD06959Q43763239-F4EBA594-4494-4E5C-B667-6512BF40A5B5Q44281592-B24C6184-E7EE-4834-B16C-84BB809B1449Q44661107-33132C6D-E707-4F96-8B76-FE413CF6614DQ44830417-7E8EB677-DBF1-404F-BCE6-624B5E99B6D1Q46463712-1FB50102-5C03-42EB-B8E8-77E8AE0FBE3AQ46830430-683F146F-9ADF-40A5-A93E-25D99D86993BQ47868737-258F24EF-D790-4803-9F62-62B7D7E0A97FQ50260074-B7E503E3-4F6F-4389-B850-7944C6095E78Q58865961-A1758DA0-DDA5-4B06-A4C9-967A9D6F3F7E
P2860
Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Allogeneic marrow transplantat ...... nalysis of prognostic factors.
@en
Allogeneic marrow transplantat ...... nalysis of prognostic factors.
@nl
type
label
Allogeneic marrow transplantat ...... nalysis of prognostic factors.
@en
Allogeneic marrow transplantat ...... nalysis of prognostic factors.
@nl
prefLabel
Allogeneic marrow transplantat ...... nalysis of prognostic factors.
@en
Allogeneic marrow transplantat ...... nalysis of prognostic factors.
@nl
P2093
P1476
Allogeneic marrow transplantat ...... nalysis of prognostic factors.
@en
P2093
C Anasetti
J E Anderson
T Chauncey
W I Bensinger
P304
P356
10.1200/JCO.1996.14.1.220
P407
P577
1996-01-01T00:00:00Z